Lupin News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Lupin Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 3
Author: Deven Choksey

Keep track of all breaking news and updates on Lupin from all sources in a single place.

Lupin Ltd.

15 May 2026

2276.20

0.80%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi.

pdf

Lupin Ltd.

14 May 2026

2276.20

0.80%

Earnings Call

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of Q4 FY2026 Earnings Conference Call.

pdf

Lupin Ltd.

14 May 2026

2276.20

0.80%

Outlook

Hold: Lupin Ltd.

Recommendation Target

Deven Choksey

The company’s near-term earnings outlook is expected to go through a transition phase rather than maintain strong growth momentum.

Deven Choksey downgraded Lupin Ltd. to Hold with a price target of 2280.0 on 14 May, 2026.

Lupin Ltd.

13 May 2026

2276.20

0.80%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives U.S. FDA Approval for Famotidine Injection, USP.

pdf

Lupin Ltd.

11 May 2026

2276.20

0.80%

Lupin (LPC IN) Q4FY26 Result Update Sustainability of US sales will be key ACCUMULATE

Accumulate: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Higher US revenues spur growth YoY: Revenues grew 33% YoY to INR 74bn, vs our estimate INR 69.4bn. Beat was on account of higher US revenues which stood at USD contribution from gTolvaptan, continued flu season and other launches. India formulation grew by 11.5% YoY. EMs increased sharply by 49%, while other developed markets increased by 7% YoY. API business showed recovery up 8% YoY....

Lupin Ltd. is trading below its 30 day SMA of 2313.8

Lupin Ltd.

10 May 2026

2276.20

0.80%

Lupin (BUY): On the verge of becoming a USD 1bn EBITDA company by FY29

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT surpassed our 4QFY26 estimates by 8.1%/18.5%/12.7% respectively; EBITDA Margin by 254 bps

Number of FII/FPI investors increased from 966 to 979 in Mar 2026 qtr.

Lupin Ltd.

09 May 2026

2276.20

0.80%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copy of Newspaper Publication regarding Audited Financial Results of the Company for the quarter and year ended March 31, 2026

pdf

Lupin Ltd.

08 May 2026

2276.20

0.80%

to see Rapid results content

Lupin Ltd.

08 May 2026

2276.20

0.80%

Lupin Q4 PAT jumps 87.7% to 1,468.7 crore

Business Line

The company had posted a consolidated profit after tax (PAT) of 782.4 crore in the corresponding quarter of the preceding fiscal, Lupin Ltd said in a regulatory filing